LOS ANGELES--(BUSINESS WIRE)--Aug. 15, 2005--St. Paul Pharmaceutical, a pending merger partner with WENR Corp. (OTC:WNRC - News; wenr.net), announced today that it is expanding its marketing of probiotic products to the Canadian, Central and South American markets.
St. Paul produces and utilizes natural fermented soy peptone in preparing its products. This eliminates any possible risk of exposure to pathogens such as BSE, Prions and viruses. Currently, St. Paul Pharmaceutical is approved to manufacture probiotics and is distributing the product in Viet Nam.
Probiotics have long been known to alleviate the symptoms of a wide range of illnesses. These "friendly bacteria" naturally exist within digestive systems. Research has suggested that probiotic bacteria can help: reduce the risk of certain diarrheal illnesses, assist lactose intolerant people with lactose digestion, decrease the risk of colon and liver cancer, provide potent immunostimulation in response to malignancies or infections (including yeast infections), treat acute gastroenteritis, treat atopic eczema resulting from food allergy, reduce pelvic radiotherapy-induced diarrhea, stop intestinal inflammation, reduce the development of allergies in children, decrease Helicobacter pylori infections, manage symptoms of inflammatory bowel disease, maintain remission of ulcerative colitis, prevent the recurrence of Crohn's disease, with the treatment in HIV positive individuals, and enhance the body's overall immune function.
The bio-supplement market contains many different product formats and contents, including capsules, liquids, tablets and even food-like formats. If properly prepared and stored, probiotic bacteria can remain viable in dried form and reach the intestine alive when consumed. Dietary supplement products are purchased primarily in health food stores or natural foods grocery stores.
WENR Corporation is a holding company that acquires technology and technology companies. It provides senior management assistance for product and market development and secures working capital.
The foregoing contains forward-looking information within the meaning of The Private Securities Litigation Act of 1995. Such forward-looking statements involve certain risks and uncertainties. The actual results may differ materially from such forward-looking statements. The company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results (expressed or implied) will not be realized.